Johnson & Johnson Inc has launched its recommended offer for Crucell NV at €24.75 per share for all of the shares it does not already own. The price is the same as that announced on 17 September, 2010 when the offer was first disclosed.
AstraZeneca Plc has signed a research agreement with the Joslin Diabetes Center in Boston, Massachusetts to use stem cells to generate new research tools for investigating the causes of Type 2 diabetes.
A public-private consortium that is investigating biomarkers for Alzheimer’s disease said data from a just-completed proteomics study which used plasma samples from a neuroimaging project is now available to download from a public website.
The unexpected early retirement of Pfizer’s chief executive and chairman, Jeffrey Kindler, drew various comments in the press with most commentators blaming his departure on the intense pressure that comes from running the world’s largest pharmaceutical company at a time when competition from generic pharmaceuticals is intensifying.
Sanofi Pasteur is withdrawing its marketing authorisation application for Emerflu, a vaccine intended for prophylaxis of influenza in the event of a pandemic involving the influenza A virus subtype, H5N1, the European Medicines Agency said.
SkyePharma Plc has updated investors on the company’s financial outlook as preparations continue for a potential launch of its asthma product, Flutiform. Revenues in 2010 are expected to show a modest increase from a year earlier.
ThromboGenics NV of Belgium has succeeded in raising €56 million through a private placement of its shares, well above the targeted amount of €35 million. A total of 2,944,523 new shares were placed with domestic and international investors.
Medivir AB of Sweden, which is a research-based speciality pharmaceutical company, has raised SEK 280 million (€30.8 million) in a private placement of its shares, more than two thirds of which were placed with institutional investors.
Merck & Co has announced plans to acquire a private US company that has developed a new insulin formulation for the treatment of diabetes mellitus. The transaction is valued at in excess of $500 million assuming milestones are met.
A US Food and Drug Administration advisory panel has voted not to recommend an expanded indication for the prostate cancer drug, dutasteride. The sponsor, GlaxoSmithKline, is seeking to have it approved for prostate cancer risk reduction.